State of the Art Sessions
Monday 25 September
CREATORS: Gabriel Oniscu, Edinburgh, United Kingdom and Jacques Pirenne, Leuven, Belgium
2017: A growing need for transplantation and changing demographics that challenge any potential increase in organ transplantation. Clinical efforts and research focus on making more organs function better and creating more organs for the ever-growing demand. The race is on: will it be organ reconditioning or creating more organs off the shelf? This session will discuss some of the recent developments that may make organ shortage a thing of the past
CHAIRS: Constantino Fondevila, Barcelona, Spain and Jacques Pirenne, Leuven, Belgium
- Organ reconditioning should start in the donor
Gabriel Oniscu, Edinburgh, United Kingdom
- Ex-situ organ reconditioning: living up to the promise?
Peter Friend, Oxford, United Kingdom
- Origami based tissue engineering
Nathaniel Hwang, Seoul, South Korea
- Choice cuts: growing organs in alternative environments
Pablo Juan Ross, Davis, United States
CREATORS: Valentin Cuervas-Mons, Madrid, Spain and Eelco de Koning, Leiden, The Netherlands
The right organ for the right patient is a central theme in transplantation. To maintain good clinical transplantation outcome is an increasing challenge in light of both donors and recipients with more unfavourable characteristics that could negatively affect this outcome. In this session we will first focus on global aspects of donation and transplantation and subsequently zoom in on 3 categories of recipients that we commonly encounter in our transplantation clinics. Sergio Leone would name them: The immunized, The old and The diabetic
CHAIRS: Valentin Cuervas-Mons, Madrid, Spain and Eelco de Koning, Leiden, The Netherlands
- World Overview on Transplantation Activities (A report of the Global Observatory on Donation & Transplantation)
Beatriz Mahillo, Madrid, Spain
- The immunized patient
Frans Claas, Leiden, The Netherlands
- The old patient
Uwe Heeman, Munich, Germany
- The diabetic patient
Raja Kandaswamy, Minneapolis, United States
CREATORS: Oriol Bestard, Barcelona, Spain and Maarten Naesens, Leuven, Belgium
Personalised medicine seems the new Holy Grail in medicine. But is it? And what has been achieved in transplantation? In this session, we discuss the experiences of large consortia that search for biomarkers in the field of transplantation. Biomarkers for non-invasive diagnosis of rejection, for guidance on immunosuppression and for patient risk stratification. In addition, we learn that the efforts to discover and validate innovative biomarkers are huge and that the pipeline towards clinical implementation is long. Finally, we look into the mirror and the crystal ball, evaluating the achievements made to date and the promises for the future.
CHAIRS: Oriol Bestard, Barcelona, Spain and Alberto Sánchez-Fueyo, London, United Kingdom
- BIOMARGIN - systems biology for non-invasive diagnosis of rejection
Wilfried Gwinner, Hannover, Germany
- BIO-DRIM - marker-assisted immunosuppression individualisation
Petra Reinke, Berlin, Germany
- CTOT - biomarkers for transplant risk stratification
Peter Heeger, New York, United States
- The biomarker verdict: prime time or perpetual promise?
Dany Anglicheau, Paris, France
Tuesday 26 September
CREATORS: Marina Berenguer, Valencia, Spain and Nicolas Mueller, Zurich, Switzerland
New genetic tools have allowed an unprecedented insight into the composition of our microbiota, and virome. first we explore the known role of the virome and microbiota specifically in transplantation. Potential clinical applications are discussed. The new anti-HCV drugs have made eradication of HCV a realistic goal in virtually all patients. We learn about the impact on transplantation on an individual and epidemiological level. And finally, the immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. How important is a complete control of viral replication?
CHAIRS: Marisa Alegre and Marina Berenguer, Valencia, Spain
- Transkingdom interplay - the complex interactive world of the microbiome
Dave Wang, St. Louis, United States
- Knowledge and clinical applications of microbiota in transplantation
Frederick Bushman, Philadelphia, United States
- Viruses and recipient immune response: relevant crosstalk in transplantation
Oriol Manuel, Lausanne, Switzerland
- The impact of HCV treatment on liver transplantation
Michael R.Charlton, Salt Lake City, United States
CREATORS: Marc Dahlke, Regensburg, Germany and Pietro Cippà, Zurich, Switzerland
Cell therapy offers great hope for being a suitable adjunct to conventional immunosuppression with all its downsights, however major issues emerged in the long translation process towards the clinic. How can technical and regulatory hurdles be overcome within a realistic time frame? Will cell therapy be commercially interesting and will its implementation relaunch solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy for tomorrow and in 10 years.
CHAIRS: Marc Dahlke, Regensburg, Germany and Thomas Wekerle, Vienna, Austria
- Technical and regulatory issues. From the idea to the clinical application
Marlies Reinders, Leiden, The Netherlands
- Sharing clinical experience. What can we learn from hematologists?
Francesco Dazzi, London, United Kingdom
- Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?
Suzanne T. Ilstad, Louisville, United States
- The future: Clinical applications of stem cells, transplantation vs. regeneration? Clinical applications of stem cells, transplantation vs. regeneration?
Alan Trouson, Clayton, Australia
CREATORS: Georg Boehmig, Vienna, Austria and Nicolas Mueller, Zurich, Switzerland
The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall quality after transplantation. It is increasingly recognized though that the ‘one size fits all’ approach does not always optimally reflect the patient’s individual need. Hence, the concept of personalized medicine is on everyone's lips. This session aims to confront the reality by asking the following questions, focusing on four important topics in the field.
CHAIRS: Georg Boehmig, Vienna, Austria and Nicolas Mueller, Zurich, Switzerland
- Is transplantation ready for systems medicine?
Rainer Oberbauer, Vienna, Austria
- Individualized antimicrobial prophylaxis
Jay Alan Fishman, Boston, United States
- Phenotypic diversity of rejection and allograft dyfunction
Phil Halloran, Edmonton, Canada
- Tailored immunosuppression
Christian Hugo, Dresden, Germany
Wednesday 27 September
CREATORS: Arne Neyrinck, Leuven, Belgium and Jacques Pirenne, Leuven, Belgium
The pre-requisite for successful transplantation is the recruitment of organs of acceptable quality in order to limit the mortality on the waiting list and to guarantee optimal short- and long-term outcome. During the last years, we have experienced a renewed interest in strategies to optimize donor management, especially since liberalization of donor criteria has been introduced within the field. In this session, we want to address the question if we can still extend the potential donor pool. Therefore the focus will be directed towards recent innovative approaches and towards potential risk factors that might limit further expansion. The session wants to involve all professionals involved, including anaesthesiologists, intensivists, nurses, coordinators and transplant physicians.
CHAIR : Arne Neyrinck, Leuven, Belgium
- How controlled is my DCD?
Sophie Van Cromphaut, Leuven, Belgium
- Should I perfuse my donor?
Simon Messer, Cambridge, United Kingdom
- Tribulation in designing donor intervention studies
Claus Niemann, San Francisco, United States
- How clean is my donor?
Margaret Hannan, Dublin, Ireland
CREATORS: Frank Dor, London, United Kingdom and Gabriel Oniscu, Edinburgh, United Kingdom
Live donation has become normal practice in many countries. The successful expansion of the acceptance criteria for live kidney donors is now challenged by emerging evidence for an increased relative risk for the development of renal failure on the long run. In this context it is even more important how transplant professionals provide tailor made information and risk assessments. How can we ensure that donors understand the potential risk? Do we have a good screening tool to assess potential psychological risk for live donors? Can we step away from standardized surgical approaches for live donor nephrectomy or is a tailor made approach more desirable? And one of the burning questions in liver transplantation currently is: Should living liver donor transplantation be advocated above deceased donor liver Tx, as is usually the case in kidney Tx ? This session focuses on the balance between Pushing the limits in the context of potential short and long-term complications.
CHAIR : Barış Akin, Ankara, Turkey
- To be or not to be a donor? (How can we make sure potential donors understand the risks?)
Aisling Courtney, Belfast, Ireland
- Psychosocial evaluation of live donors - the need for a tool to determine psychological risk
Fabienne Dobbels, Leuven, Belgium
- Tailor Made Live Donor Nephrectomy: a conversation between 2 surgeons
Frank Dor, London, United Kingdom and Gabriel Oniscu, Edinburgh, United Kingdom
- Should live liver donor transplantation be advocated above deceased donor liver Tx?
Yaman Tokat, Istanbul, Turkey
CREATORS: Lorna Marson, Edinburgh, United Kingdom and Olivier Thaunat, Lyon, France
Transplant rejection involves a coordinated attack of the graft by the innate and the adaptive immune systems of the recipient. Although direct visualization of this complex cellular interplay, made possible by recent technological progresses, has greatly improved our understanding of rejection pathophysiology, it has also led to unexpected observations. Indeed, like in other chronic inflammatory conditions, organized lymphoid tissue develops within allografts. This session will provide an update on cellular interactions in rejection and will discuss whether intragraft tertiary lymphoid organs contribute to graft rejection and/or tolerance.
CHAIRS: Henri Leuvenink, Groningen, The Netherlands and Wilson Wong, London, United Kingdom
- Visualizing cell traficking underlying allosensitization by two-photon microscopy
Menna Clatworthy, Cambridge, United Kingdom
- T cell migration to vascularized transplants
Fadi Lakkis, Pittsburgh, United States
- Lymphoid neogenesis: a tribute to the travellers
Nancy Ruddle, New Haven, United States
- Intragraft tertiary lymphoid organs: friends and foes
Olivier Thaunat, Lyon, France